Evaluation of controlled attenuation parameter in assessing hepatic steatosis in patients with autoimmune liver diseases

Table 2 Diagnostic performance of controlled attenuation parameter for assessment of hepatic steatosis in patients with mixed etiology liver disease and in patients with autoimmune liver diseases

Etiology	Grade	AUROC (95%CI)	Cut-off, dB/m (kPa)	Sensitivity	Specificity	PPV	NPV
Mixed etiology	S ≥ 1	0.883 (0.807-0.958)	229	0.852	0.714	0.960	0.375
	S ≥ 2	0.772 (0.705-0.838)	259	0.875	0.636	0.636	0.875
	S = 3	0.732 (0.640-0.824)	283.5	0.750	0.654	0.273	0.938
AILDs	S ≥ 1	0.878 (0.791-0.965)	220.5	0.874	0.737	0.937	0.538
	S ≥ 2	0.764 (0.676-0.853)	271.5	0.818	0.704	0.510	0.937
	S = 3	0.821 (0.716-0.926)	283.5	1.000	0.688	0.128	1.000

AUROC: Area under receiver operating characteristic; CAP: Controlled attenuation parameter; NPV: Negative predictive value; PPV: Positive predictive value.